Additional file 17 of Potentiation of cord blood cell therapy with erythropoietin for children with CP: a 2 × 2 factorial randomized placebo-controlled trial
posted on 2020-11-28, 04:48authored byKyunghoon Min, Mi Ri Suh, Kye Hee Cho, Wookyung Park, Myung Seo Kang, Su Jin Jang, Sang Heum Kim, Seonkyeong Rhie, Jee In Choi, Hyun-Jin Kim, Kwang Yul Cha, MinYoung Kim
Additional file 17. Gene expression of IL-1β among responders vs. non-responders in groups A and B. Legends: Group A (UCB + EPO) and group B (UCB + P-EPO) were re-grouped into 2 groups as responder subgroup and non-responder subgroup, where responder (n = 13) subgroup refers to those who showed improvements in GMFCS levels and non-responders (n = 20) refers to those who did not show improvements in GMFCS levels at 12 months post-intervention. Gene expression assay with RT-PCR showed bigger increment in IL1-β mRNA level in their relative values to the baseline level (D-4) at 3 d (D+3; P = 0.032) and 10 d (D+10; P = 0.013) post-intervention when comparing responder subgroup (dark-pink) with non-responder subgroup (light pink). *P < 0.05 by Mann-Whitney U test. Abbreviations: GMFCS, Gross Motor Functional Classification System; IL, interleukin; RT-PCR, reverse transcription polymerase chain reaction.
Funding
Health Promotion Administration, Ministry of Health and Welfare